A Phase 3, Randomized, Observer-Blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza in Healthy Individuals

Project: Research project

Project Details

StatusActive
Effective start/end date11/15/23 → 11/14/28

Funding

  • Pfizer, Inc.: $13,842.00